UnipharDUB:UPR -0.88%82 PEG Ratio is 1.25 as of Jun. 30, 2026, which is 51% above its 10-year median of 0.83. GuruFocus rates DUB:UPR with a GF Score™ of 82/100 and a GF Value™ of €3.64 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 48 Medical Distribution companies, Uniphar ranks better than 66.67% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Uniphar's PE Ratio without NRI is 18.27. Uniphar's 5-Year EBITDA growth rate is 14.60%. Therefore, Uniphar's PEG Ratio for today is 1.25.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Uniphar's PEG Ratio or its related term are showing as below:
DUB:UPR'
s PEG Ratio Range Over the Past 10 Years
Min: 0.21 Med: 0.83 Max: 1.44
Current: 1.25
During the past 10 years, Uniphar's highest PEG Ratio was 1.44. The lowest was 0.21. And the median was 0.83.
DUB:UPR's PEG Ratio is ranked better than 66.67% of 48
companies
in the Medical Distribution industry
Industry Median: 1.84
vs DUB:UPR: 1.25
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Uniphar (DUB:UPR) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Uniphar PEG Ratio Related Terms
Uniphar PEG Ratio Historical Data
* Premium members only.
The historical data trend for Uniphar's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Uniphar's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Uniphar PEG Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Uniphar's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Uniphar's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Uniphar (DUB:UPR) has a PEG Ratio of 1.25 as of Jun. 30, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Uniphar and its competitors. This is 51% above median its historical median of 0.83. Over the past decade, Uniphar's PEG Ratio has ranged from 0.21 to 1.44. According to the industry distribution chart, Uniphar ranks #16 out of 48 companies in the Medical Distribution industry, placing it in the top 33.3%.
Is Uniphar's PEG Ratio too high?
Uniphar's current PEG Ratio of 1.25 is 51% above median its 10-year median of 0.83. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 1.44. The Medical Distribution industry median PEG Ratio is 1.84. Uniphar's value of 1.25 is 32.1% below this industry median. Based on the distribution chart, Uniphar ranks #16 out of 48 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Uniphar has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's PEG Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Uniphar ranks #16 out of 48 companies for PEG Ratio. This puts Uniphar in the upper half of its industry. The industry median PEG Ratio is 1.84. Uniphar's value of 1.25 is 32.1% below this benchmark. Historically, Uniphar's own PEG Ratio has ranged from 0.21 to 1.44 over the past decade. While the company's 10-year median is 0.83 vs. the industry median of 1.84, Uniphar has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Distribution company?
The median PEG Ratio among Medical Distribution companies is 1.84, based on 48 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Uniphar's current PEG Ratio of 1.25 is 32.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Uniphar and its competitors. For the Medical Distribution industry, the median PEG Ratio is 1.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Uniphar's current PEG Ratio is 1.25, which is 51% above median its own 10-year median of 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.64, compared to a current price of €4.53 — trading 24.5% above its estimated fair value. The current PEG Ratio is 1.25, which is 51% above median its 10-year median of 0.83 and 32.1% below the Medical Distribution industry median of 1.84. Uniphar's overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current PEG Ratio is 1.25 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uniphar (DUB:UPR) Overvalued in 2026?
Based on GuruFocus' analysis, Uniphar stock appears to be overvalued.
The current stock price of €4.53 is trading 24.5% above its estimated GF Value™ of €3.64.
GuruFocus considers Uniphar to be Modestly Overvalued.
Key valuation signals for DUB:UPR:
PEG Ratio: 1.25 (51% above median its 10-year median of 0.83)
GF Value™: €3.64 vs. price of €4.53 (24.5% above fair value)
Industry Position: 32.1% below the Medical Distribution median (#16 of 48)
No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
82GF Score
Get the complete analysis for DUB:UPR
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DUB:UPR has been successfully added to your 
